IL17A and diabetic kidney disease: Our previous study revealed that dosing recombinant cytokine IL-22 for enhancing the repairment of renal damage showed effective synergy with VEGF-B antibody (for rebalancing lipid metabolism) to ameliorate DKD progression [22], and transcriptomics analysis indicated that IL-17A signaling was highly involved in anti-VEGF-B-IL-22 treatment [22].